Bioporto A/S
CSE:BIOPOR
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.222
2.965
|
| Price Target |
|
We'll email you a reminder when the closing price reaches DKK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Bioporto A/S
Bioporto A/S
Cash from Financing Activities
Bioporto A/S
Cash from Financing Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Financing Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Bioporto A/S
CSE:BIOPOR
|
Cash from Financing Activities
kr74.8m
|
CAGR 3-Years
-7%
|
CAGR 5-Years
0%
|
CAGR 10-Years
6%
|
|
|
Genmab A/S
CSE:GMAB
|
Cash from Financing Activities
-kr3.6B
|
CAGR 3-Years
-108%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Zealand Pharma A/S
CSE:ZEAL
|
Cash from Financing Activities
kr8.3B
|
CAGR 3-Years
132%
|
CAGR 5-Years
66%
|
CAGR 10-Years
N/A
|
|
|
Ascendis Pharma A/S
NASDAQ:ASND
|
Cash from Financing Activities
€437.8m
|
CAGR 3-Years
5%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
N/A
|
|
|
B
|
Bavarian Nordic A/S
CSE:BAVA
|
Cash from Financing Activities
-kr35.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
35%
|
CAGR 10-Years
-22%
|
|
|
F
|
Fluoguide AS
STO:FLUO
|
Cash from Financing Activities
kr27.5m
|
CAGR 3-Years
17%
|
CAGR 5-Years
241%
|
CAGR 10-Years
N/A
|
|
Bioporto A/S
Glance View
Bioporto A/S engages in the provision of diagnostic tests and antibodies to healthcare professionals in clinical and research settings. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.
See Also
What is Bioporto A/S's Cash from Financing Activities?
Cash from Financing Activities
74.8m
DKK
Based on the financial report for Jun 30, 2024, Bioporto A/S's Cash from Financing Activities amounts to 74.8m DKK.
What is Bioporto A/S's Cash from Financing Activities growth rate?
Cash from Financing Activities CAGR 10Y
6%
Over the last year, the Cash from Financing Activities growth was 87%. The average annual Cash from Financing Activities growth rates for Bioporto A/S have been -7% over the past three years , and 6% over the past ten years .
You don't have any saved screeners yet
